Kathryn-Ann
Stamm

On November 4, 2024, DRI Healthcare Trust (“the Trust”), a global leader in providing financing to advance innovation in the life sciences industry, announced it has acquired a royalty interest in the worldwide net sales of all formulations of sebetralstat, an investigational oral plasma kallikrein inhibitor for the treatment of Hereditary Angioedema, from KalVista Pharmaceuticals ("KalVista") for an aggregate purchase price of up to $179 million, comprised of a $100 million upfront payment, up to $57 million in a sales-based milestone payment and a one-time $22 million optional payment. Additionally, the Trust is making a $5 million investment in KalVista’s common stock in a private placement transaction. Cravath is representing DRI Healthcare Trust in connection with the transaction.

On October 4, 2024, Vista Outdoor Inc. (“Vista Outdoor”), the parent company of more than three dozen renowned brands that design, manufacture and market sporting and outdoor products, announced it has entered into a definitive agreement with funds managed by Strategic Value Partners, LLC, and its affiliates (“SVP”), a global alternative investment firm with approximately $19 billion of assets under management, to sell Revelyst in an all‑cash transaction based on an enterprise value of $1.125 billion. In connection with the SVP Transaction, Vista Outdoor also entered into an amendment to the merger agreement with Czechoslovak Group a.s. (“CSG”) to acquire The Kinetic Group, increasing the purchase price for The Kinetic Group to $2.225 billion. Together, the CSG Transaction and the SVP Transaction represent an enterprise value of $3.35 billion for Vista Outdoor and will deliver an estimated $45 per share in cash to Vista Outdoor stockholders. Cravath is representing Vista Outdoor in connection with the transaction.

On October 3, 2024, DRI Healthcare Trust, a global leader in providing financing to advance innovation in the life sciences industry, announced that one of its wholly owned subsidiaries acquired a portion of Editas Medicine, Inc.'s payment rights under a non‑exclusive license of Editas' Cas9 gene‑editing technology for CASGEVY®, the only approved gene‑edited cell therapy for sickle cell disease and transfusion‑dependent beta thalassemia, for an upfront purchase price of $57 million. The transaction entitles DRI Healthcare to specific payments based on a sublicensing agreement between Editas and Vertex Pharmaceuticals Incorporated. The payments include a share of the annual license fees that Vertex pays to Editas, which can range from $5 million to $40 million, including certain sales‑based annual license fee increases, and a portion of a $50 million contingent payment to which Editas is eligible under the Vertex sublicensing agreement. Cravath is representing DRI Healthcare in connection with the transaction.

On September 5, 2024, Verizon Communications Inc. and Frontier Communications Parent, Inc. (“Frontier”), the largest pure‑play fiber provider in the U.S., announced they have entered into a definitive agreement for Verizon to acquire Frontier in an all‑cash transaction valued at $20 billion. Cravath is representing Frontier in connection with the transaction.

On February 12, 2024, Martin Marietta Materials, Inc. (“Martin Marietta”) announced that on February 11, 2024, it entered into a definitive agreement to acquire 20 active aggregates operations in Alabama, South Carolina, South Florida, Tennessee, and Virginia from affiliates of Blue Water Industries LLC (“BWI Southeast”) for $2.05 billion in cash. Additionally, on February 9, 2024, Martin Marietta completed its previously announced divestiture of its South Texas cement and related concrete operations to CRH Americas Materials, Inc., a subsidiary of CRH plc, for $2.1 billion in cash. Cravath is representing Martin Marietta in connection with the transactions.

Cravath partners David J. Kappos and Sasha Rosenthal‑Larrea, of counsel Kathryn‑Ann Stamm and associate Lucille Dai‑He co‑authored an article entitled “Enhancing Cybersecurity Readiness With a Software Bill of Materials,” which was published in Bloomberg Law on June 5, 2024. The article explores the increasing importance of Software Bills of Materials (“SBOMs”) in cyber readiness for organizations, detailing how SBOMs can enhance security, license compliance, incident response, and their significance in the diligence process.

In May 2024, the World Intellectual Property Review named Cravath of counsel Kathryn‑Ann Stamm as part of its 2024 Diversity Top 100 list. Recognized as an IP Trailblazer, WIPR considers Kathryn‑Ann to be one of the “outstanding people with a decade or less of experience in the IP industry who have already made their mark on the sector.”

Cravath of counsel Kathryn-Ann Stamm participated in the African Women Entrepreneurship Cooperative’s 2024 General Assembly, which was held from April 17‑19, 2024, in Gaborone, Botswana. The event convened women entrepreneurs and business leaders, experts and executives from across the globe to discuss how to build partnerships and the value of collaboration in entrepreneurship. Kathryn‑Ann led a multi‑day learning lab entitled “The Elements of Win‑Win Partnerships,” which equipped attendees with an in‑depth roadmap to prepare, create and nurture mutually beneficial partnerships for their businesses. Through the learning lab, Kathryn‑Ann provided attendees with a comprehensive toolkit, empowering them to successfully navigate the lifecycle of partnerships while effectively protecting their own business interests and intellectual property.

On November 17, 2023, Virginia M. Anderson, D. Ana Choi, Christopher P. Davis, Janice T.P. Martindale, Flora Ng, Nicole M. Peles, Scott B. Reents and Kathryn‑Ann Stamm were named of counsels of the Firm and Jean Kearns and DongHwa Kim were named senior attorneys of the Firm, effective January 1, 2024.